10-Q: DSwiss Inc. Reports Declining Revenue, Net Loss in Q2 2026

DSwiss, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, revealing a significant decrease in revenue and a net loss, alongside substantial doubt about its going concern status.

Summary

• DSwiss, Inc. reported a substantial decrease in revenue for the three and six months ended June 30, 2026, compared to the same periods in 2025.
• The company incurred a net loss of $2,502 for the three months ended June 30, 2026, and a net profit of $1,789 for the six months ended June 30, 2026.
• This contrasts with net profits of $32,128 and $170,864 for the respective periods in 2025.
• The company's current liabilities exceeded its current assets by $91,418 as of June 30, 2026, and it has an accumulated deficit of $1,463,001.
• Management has identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient written policies and procedures.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues, net losses, and significant concerns regarding the company's ability to continue as a going concern.

Positives

• Gross profit for the three months ended June 30, 2026, increased by $20,746 compared to the same period in 2025, reaching $169,354.
• The company has a significant amount of net operating loss carryforwards in the US ($668,553), Hong Kong ($623,512), and Malaysia ($123,950) that can offset future taxable income.
• The company's principal executive officer and principal financial officer have certified the accuracy of the financial reporting.

Negatives

• Revenue for the three months ended June 30, 2026, was $511,781, a decrease from $1,021,340 in the prior year period.
• Revenue for the six months ended June 30, 2026, was $989,518, a decrease from $2,022,526 in the prior year period.
• The company reported a net loss of $2,502 for the three months ended June 30, 2026.
• The company has negative operating cash flow of $5,298 for the six months ended June 30, 2026.
• Current liabilities exceeded current assets by $91,418 as of June 30, 2026, raising substantial doubt about the company's ability to continue as a going concern.
• There are material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient written policies and procedures.

Risks

• The company's ability to continue as a going concern is dependent upon improving its profitability and the continuing financial support from its shareholders.
• Future financing, if needed, may contain undue restrictions on operations or cause substantial dilution for stockholders.
• The company is exposed to exchange rate risk due to fluctuations in the RM to US$ and HK$ to US$ exchange rates.
• Concentration of revenue from major customers, with Customer A accounting for 61% of revenue in the six months ended June 30, 2026.
• Concentration of purchases from major vendors, with Vendor A accounting for 57% of purchases in the six months ended June 30, 2026.

Future Outlook

The company expects its current capital resources to meet its basic operating requirements for approximately twelve months. Expected growth is planned to occur primarily through the implementation of a social media marketing strategy and forming partnerships with local companies in various countries for global expansion.

Management Comments

• Management believes the existing shareholders or external financing will provide the additional cash to meet the Companys obligations as they become due.
• The results of operations for the periods ended June 30, 2026 and 2025 presented are not necessarily indicative of the results to be expected for the full year.
• Management has identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient written policies and procedures.

Industry Context

StockSavvy.ai notes that the biotech-nutraceutical and beauty supplies industry, particularly in the ASEAN region, is competitive. DSwiss's focus on OEM/ODM services and private label manufacturing aligns with industry trends for companies seeking to outsource production. However, the reported decline in revenue and net loss, coupled with going concern issues, suggests significant operational challenges in a market that often relies on strong brand building and consistent product innovation.

Comparison to Industry Standards

• The company's gross margin calculation excludes certain distribution network costs, making direct comparison to industry standards difficult without further clarification.
• The reported net loss for the quarter and minimal profit for the six months are concerning when compared to typically growing companies in the biotech and beauty sectors, which often aim for consistent profitability.
• The significant net operating loss carryforwards suggest a history of unprofitability, which is not uncommon for early-stage or growth-focused companies, but DSwiss's current financial state raises concerns about its ability to leverage these for future tax benefits.

Corporate Governance

Legal Proceedings

• No material, active, or pending legal proceedings against the company are known.

Related Party Transactions

• Professional fees paid to Related party A (subsidiary of a 7.33% shareholder) were $3,350 for the six months ended June 30, 2026.
• Sales to Related party C (director/founder) were $127,167 for the six months ended June 30, 2026.
• Purchases from Related party D (director/founder) were $375,167 for the six months ended June 30, 2026.
• Transactions are generally conducted on an arm's length basis at current market value.

Stakeholder Impact

• Shareholders may face dilution if future financing is equity-based, or operational restrictions if debt-financed.
• The going concern issue poses a significant risk to all stakeholders, potentially impacting the company's ability to meet its obligations.
• Employees may face uncertainty regarding job security due to the company's financial condition.
• Suppliers may face risks related to payment delays or defaults given the company's liquidity challenges.

Next Steps

• Management believes existing shareholders or external financing will provide necessary cash to meet obligations.
• The company plans to implement a social media marketing strategy for growth.
• The company intends to expand globally by forming partnerships with local companies.
• Continued focus on product research and development for functional food and beauty products.
• Ongoing efforts to maintain high product quality standards certified by the Ministry of Health (MOH) Malaysia.

Key Dates

Recommendation

The filing indicates a worsening financial situation with declining revenues, net losses, and significant going concern issues. Material weaknesses in internal controls further exacerbate the risk. The company's ability to continue operations is in doubt without further financial support, making it a high-risk investment.

Keywords

biotech-nutraceutical, beauty supplies, medical consumables, OEM/ODM, private label, skincare, functional food, Malaysia